Cardiovascular clinical trials market seen growing to $7.7 billion by 2030

The cardiovascular clinical trials market is projected to expand from $5.72 billion in 2025 to $7.7 billion by 2030, according to a new report from The Business Research Company. The outlook is being driven by rising heart disease rates, faster trial tech adoption and more decentralized study designs.

Why it matters: - Cardiovascular disease remains a major global health burden, so faster and more efficient clinical trials affect how quickly new heart treatments reach patients. - The market’s projected growth signals stronger demand for trial services, data tools and research infrastructure across cardiology. - The shift toward decentralized, AI-enabled and patient-centered trials could change how cardiovascular studies are run.

What happened: - The Business Research Company published its Cardiovascular Clinical Trials Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report estimates the cardiovascular clinical trials market will rise from $5.72 billion in 2025 to $6.12 billion in 2026. - The report forecasts the market will reach $7.7 billion by 2030, implying a 5.9% CAGR over the forecast period. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Cardiovascular clinical trials study new ways to prevent, diagnose, treat and manage heart and vascular diseases, including coronary artery disease, heart failure, arrhythmias and hypertension. - The trials typically test drugs, devices or procedures tied to heart health and stroke prevention. - Market growth has been supported by higher cardiovascular disease prevalence, more global clinical research activity, faster regulatory approvals, established trial infrastructure and more multicenter studies. - The report points to demand for quicker trial completion, AI-driven analytics, remote patient engagement, patient-centric trial design and greater investment in cardiovascular drug pipelines as additional growth drivers. - The report highlights decentralized trial models, digital patient monitoring, biomarker integration, real-world evidence generation and adaptive trial methods as key trends. - In Minnesota, the state Department of Health reported in September 2024 that nearly 30% of adults had high blood pressure in 2023, or about 1.4 million people. - The same state data said hypertensive diseases caused 14,225 deaths in 2022, close to 28% of statewide mortality. - The report says Asia-Pacific growth is being driven by expanding healthcare infrastructure, more clinical research investment, a rising disease burden and regulatory reforms. - The report also covers South East Asia, Western and Eastern Europe, South America, the Middle East and Africa. - The 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables. - The report is available as a free sample sample request. - The full report is available here.

Between the lines: - The projected slowdown from 7.0% growth in 2026 to a 5.9% CAGR through 2030 suggests a market that is still expanding, but at a more moderate pace. - The emphasis on remote data collection and decentralized trials reflects pressure to reduce costs, speed enrollment and improve participation. - The report’s regional split suggests mature markets like North America will remain important, while growth will increasingly come from faster-expanding Asian markets.

What's next: - More cardiovascular studies are likely to adopt digital monitoring, biomarker-driven endpoints and adaptive protocols. - Trial sponsors may continue shifting investment toward technologies that shorten study timelines and improve retention. - Asia-Pacific could capture a larger share of new trial activity if infrastructure and regulatory reforms continue.